Haselmeier licenses Axis-D pen injector to Stevanato Group
Haselmeier said today that it entered into an exclusive agreement with Stevanato Group to license the Axis-D pen injector and intellectual property for the development, manufacturing and supply of the device for diabetes care.
Haselmeier’s Axis-D auto-injector pen is approved for use by the European Medical Agency and the FDA, among other regulatory bodies. The Zurich-based company said its pens are designed to be convenient, precise in dosing and enable an enhanced patient experience to support therapy efficiency.
Stevanato Group plans to use the Axis-D pen technology for the treatment of diabetes all over the world. Once the device has been designed, the company plans to produce it at one of its manufacturing facilities. The Piombino Dese, Italy-based company said it will provide sub-assembly and final assembly equipment from its operations in Denmark.
“We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in Diabetes,” Haselmeier chief innovation officer Frédéric Gabriel said in prepared remarks. “Stevanato Group has demonstrated in past years a consistent development strategy coupled with unique integrated capabilities and is able to leverage Haselmeier’s pen injection platform to bring it to the next level. Such platform has already been proven in the market, from an IP, performance and user perspective. It also demonstrates Haselmeier’s strategic orientation to exploit its IP over various paths, either with own development and manufacturing capabilities or together with a strategic partner.”
“Consistent with its vision Stevanato Group always welcomes strategic agreements with key players in the market to broaden its global capabilities” added Stevanato Group chief technology officer Paolo Patri. “We value our relationship with Haselmeier as a device technology partner. With this agreement, we continue to expand our portfolio of devices for patients suffering from diabetes. This complements ongoing work on our award winning 1ml cartridge-based wearable device, which will give our biopharmaceutical partners the opportunity to provide patients with both standard and alternative treatment solutions with such devices. “